Operating In An Unsettled FDA Environment

In this segment from the Life Science Leader Live event "FDA Engagement Strategies and Best Practices Amid Agency Changes," Jeremy Levin, Jeremy Levin, Co-Founder and Executive Chairman, Ovid Therapeutics, advises companies not to "read Washington tea leaves" or redesign development plans reactively. Companies should focus instead on sharpening their questions and documenting what they hear directly from the agency.